NIPPON CHEMIPHAR CO., LTD.

Dropscreen, an allergy screening device and reagent that can measure 41 allergens in 30 minutes from just one drop of blood, exceeded 1,800 cumulative domestic installations as of the end of FY2026 (ending March 2026). Sales of clinical diagnostic reagents for the fiscal year expanded steadily to ¥5,436 million (up 11.3% year on year), supported by product strength that captures the need for in-house testing at hospitals, driving continued adoption.

The company operates the Nippon Chemiphar Tsukuba Plant (installation work for new facilities on the 2nd floor of Building No. 3 completed in August 2024, with shipments starting from May 2026) and a Vietnam plant (Nippon Chemiphar Vietnam Co., Ltd.), building a structure in which development, manufacturing, and sales are handled consistently within its own group. The Vietnam plant has also begun contract manufacturing for other companies' products, with a group-wide quality assurance division ensuring quality control at the same level as in Japan.

NC-2800, a delta opioid receptor agonist, began case enrollment for a Phase IIa clinical trial at 27 domestic institutions from January 2026. DFP-14323, an anticancer drug candidate, is undergoing a Phase III trial at approximately 30 domestic institutions. For DFP-17729, targeted at pancreatic cancer, case enrollment for the Phase II portion of a Phase II/III trial was completed in May 2026. R&D expenses of ¥2,134 million have been invested.

New equipment on the 2nd floor of Building No. 3 at Nihon Yakuhin Kogyo Co., Ltd.'s Tsukuba Plant will begin sequential product shipments from May 2026. The company is strengthening inter-company collaboration, including participation in a consortium concept involving multiple Generic Drugs companies, to build a supply system capable of responding to increased demand associated with changes in the drug price positioning of authorized generics (AG).

As of the end of FY2026 (ending March 2026), the cumulative number of domestic installations exceeded 1,800 units, and sales of clinical diagnostic reagents were solid at ¥5,436 million (up 11.3% year on year). The company continues to expand its sales structure while promoting product improvements and manufacturing cost reductions. Product development for overseas expansion, regulatory compliance in various countries, and partner selection are also underway.

Enrollment for the Phase IIa clinical trial of the delta opioid receptor agonist "NC-2800" began in January 2026 at 27 sites in Japan. Development is being advanced under a joint research and development and option agreement with Sumitomo Pharma Co., Ltd., with support from AMED's "CiCLE Program." Efficacy and safety are being evaluated in a double-blind comparative trial targeting patients with depression.

In Vietnam, sales of "Rebamipide Tablets 100mg" and "Febuxostat Tablets 80mg" are expanding, and approval for "Allopurinol Tablets 100mg" was obtained in March 2026. In China, products such as "Epinastine Hydrochloride Tablets 20mg" are being exported. For the Middle East and Africa, under an advisory agreement with the IFC, the company is narrowing down target countries and partners and negotiating products. As of the end of March 2026, products were being sold in 4 countries across 8 items.

"DFP-17729," based on a licensing agreement with Delta-Fly Pharma, Inc., is undergoing enrollment at 16 domestic sites in a Phase II/III trial targeting pancreatic cancer patients that began in March 2025. Completion of enrollment for the Phase II portion is expected around July 2026. In the chronic kidney disease field, a physician-initiated clinical study at Nagoya University is also underway.